Danone Q3 results 'buoyed' by Asian infant formula recovery

By Mark ASTLEY

- Last updated on GMT

Asia infant formula sales are "now back to pre-crisis levels," says Danone.
Asia infant formula sales are "now back to pre-crisis levels," says Danone.

Related tags Fresh dairy products Milk

The continuing recovery of Danone’s infant formula business, impacted by the 2013 Fonterra whey protein concentrate (WPC) botulism scare, has “buoyed” the French dairy's Q3 results.

In its financial results for the three months ended September 30 2014, published yesterday, Danone reported a 3% increase in revenue from €5.259bn (US$6.7bn) in Q3 2013 to €5.419bn (US$6.9bn).

The Paris-based company attributed the increase in sales to "solid trends across all businesses, underpinned by a favorable basis for comparison in Early Life Nutrition."

The Early Life Nutrition division, which produces specialty foods for babies and young children, reported sales of of €1.054bn (US$1.34bn) in Q3 - up 17.3% on the €924m (US$1.18bn) reported for the same three-month period of 2013. 

Danone experienced a “very steep decline” in sales in Q3 on the back of the recalls triggered by Fonterra’s August 2 2013 WPC botulism alert.

Fonterra alerted eight customers, including Danone-owned Dumex and Nutricia Australia New Zealand (Nutricia ANZ), that three batches of WPC potentially contaminated with Clostridium botulinum had entered the supply chain.

Tests later revealed that the bacteria found in the three WPC batches were Clostridium sporogenes, a non-toxic Clostridium strain.

This information came too late, however, for Nutricia ANZ and Dumex, who pulled infant formula from shelves in New Zealand, Cambodia, Thailand, Laos, Hong Kong, China, Malaysia, and Singapore, without proof their products were tainted. 

Sales in the eight markets are "now back to pre-crisis levels,"​ said Danone in its Q3 results.

“In China, the market that was hardest hit, Group brands as a whole continued to grow broadly in line with expectations,​" it added.

Danone's Fresh Dairy Products business, the company's largest segment, meanwhile reported sales of €2.796bn (US$3.57bn) for the third quarter of 2014, down 4% from €2.913bn (US$3.71bn) in Q3 2013.

It attributed the fall in sales to a “continued decline in sales volumes”​ in Europe and “slower growth”​ in North America and, as a result of the current situation in Ukraine, the CIS region. 

“In Russia, growth remains buoyed by continued portfolio enhancement through higher prices and a very positive mix effect; low value-added segments have continued to decline in volume, affecting sales in both the geographical area and the division,"​ said Danone.

"For the CIS as a whole, growth has in any case tapered off since the beginning of the year due to the negative performance of Ukraine.”

In the US meanwhile, the growth of Danone's Fresh Dairy Products division is "leveling off after several years of strong dynamic, particularly in Greek yogurt."

Based on its results for the first nine months of the year, Danone reconfirmed its 2014 sales growth target of between 4.5% and 5.5%.

Related news

Related products

4 reasons children need MFGM, according to science

4 reasons children need MFGM, according to science

Content provided by Valio | 29-Sep-2023 | White Paper

In this white paper, Dr Anu Turpeinen discusses the ample scientific evidence showing why milk fat globule membrane (MFGM) is essential for children’s...

Introducing a new era in infant nutrition

Introducing a new era in infant nutrition

Content provided by dsm-firmenich | 01-Sep-2023 | Research Study

Omega-3s are critical to infant health and development – but conventional omega-3 ingredients are impacting the planet.

Solutions of Amino Acids-Based Infant Formula

Solutions of Amino Acids-Based Infant Formula

Content provided by INNOBIO Corporation Limited | 22-Jun-2023 | White Paper

Many infants who are born with nutritional defects often need specifically developed infant formulas to maintain their growth and development. Amino acids-based...

LIPOFER™: a bioavailable and stable source of iron

LIPOFER™: a bioavailable and stable source of iron

Content provided by Lipofoods, a Lubrizol Company | 26-Apr-2023 | White Paper

Maintaining adequate iron levels is critical to maintaining a healthy body, with deficiencies being the cause of several health issues including anemia...

Related suppliers

Follow us

Products

View more

Webinars